Goldman, J. W. Et Al. 2021. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. LANCET ONCOLOGY , vol.22, no.1 , 51-65.

Goldman, J. W., Dvorkin, M., Chen, Y., Reinmuth, N., Hotta, K., Trukhin, D., ... Statsenko, G.(2021). Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. LANCET ONCOLOGY , vol.22, no.1, 51-65.

Goldman, Jonathan Et Al. "Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial," LANCET ONCOLOGY , vol.22, no.1, 51-65, 2021

Goldman, Jonathan W. Et Al. "Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial." LANCET ONCOLOGY , vol.22, no.1, pp.51-65, 2021

Goldman, J. W. Et Al. (2021) . "Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial." LANCET ONCOLOGY , vol.22, no.1, pp.51-65.

@article{article, author={Jonathan W. Goldman Et Al. }, title={Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial}, journal={LANCET ONCOLOGY}, year=2021, pages={51-65} }